S&P 500 Industrials Sector SEC Filings — February 12, 2026

13-02-2026

COLUMBIA BANKING SYSTEM, INC. filed an 8-K on February 13, 2026 (AccNo: 0000887343-26-000039, Size: 217 KB) reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the nature of the other events or contents of the exhibits are disclosed in the filing metadata. This is a multi-item filing with no quantitative metrics, comparisons, or directional indicators provided.

13-02-2026

Moderna, Inc. filed an 8-K on February 13, 2026 (AccNo: 0001682852-26-000015), reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, period-over-period comparisons, or other quantitative financial metrics are disclosed in the provided filing information. No positive, negative, or flat performance indicators were mentioned.

• ·AccNo: 0001682852-26-000015
• ·Sector: not specified

13-02-2026

13-02-2026

Sound Financial Bancorp, Inc. filed a Form 8-K on February 13, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events, transaction values, financial metrics, or exhibits are disclosed in the provided filing information. This is a multi-item filing with limited transparency on content.

13-02-2026

SunHydrogen, Inc. filed an 8-K on February 13, 2026 (AccNo: 0001213900-26-015747, Size: 380 KB), reporting under Item 1.01 entry into a material definitive agreement and under Item 9.01 financial statements and exhibits. No specific details on the agreement, transaction value, parties, financial impacts, or other metrics are disclosed. This is a multi-item mandatory filing with no period-over-period comparisons or quantitative data provided.

13-02-2026

Enbridge Inc filed an 8-K on February 13, 2026, under Item 2.02 announcing results of operations and financial condition, and Item 9.01 providing financial statements and exhibits. No specific revenue, earnings, balance sheet changes, guidance, or period-over-period comparisons are disclosed in the provided filing information. No positive or negative metrics, transaction details, or scheduled events are mentioned.

13-02-2026

13-02-2026

GENCO SHIPPING & TRADING LTD filed an 8-K on 2026-02-13 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 indicates Financial Statements and Exhibits were included. No specific details on the affected position, names, reasons, or timing were disclosed.

13-02-2026

Citius Pharmaceuticals, Inc. filed a Form 8-K on February 13, 2026 (AccNo: 0001213900-26-015895), disclosing under Item 3.01 a notice of delisting or failure to satisfy a continued listing rule or standard, and under Item 2.02 results of operations and financial condition. Item 9.01 references financial statements and exhibits. This multi-item filing highlights a material compliance failure with exchange listing requirements, with no specific financial metrics or performance details provided.

• ·Multi-item 8-K filing (Items 2.02, 3.01, 9.01)
• ·Event date aligns with filing date: 2026-02-13

13-02-2026

MOVING iMAGE TECHNOLOGIES INC. filed an 8-K on February 13, 2026 (AccNo: 0001437749-26-004067, Size: 307 KB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, balance sheet effects, guidance, or period-over-period comparisons were disclosed in the filing metadata. This is a multi-item voluntary disclosure typical for earnings releases.

13-02-2026

Data Storage Corp filed an 8-K on February 13, 2026, disclosing an event under Item 5.02 related to departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 indicates financial statements and exhibits were included. No specific details on affected positions, individuals, reasons for changes, or any quantitative metrics are disclosed.

13-02-2026

HECLA MINING CO/DE/ filed an 8-K on February 13, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific financial metrics, transactions, or operational details are disclosed in the filing metadata. Critical content of the disclosure is missing, limiting analysis.

13-02-2026

Invesco Mortgage Capital Inc. filed a Form 8-K on February 13, 2026, under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific transaction details, financial metrics, or events described in the provided information. Core event and impacts remain undisclosed.

13-02-2026

Zenas BioPharma, Inc. filed an 8-K on 2026-02-13 disclosing officer changes under Item 5.02, including potential departures of directors or certain officers, elections of directors, appointments of certain officers, and compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific names, positions, reasons for changes, financial metrics, or quantitative details are disclosed.

13-02-2026

Bayview Acquisition Corp filed an 8-K on February 13, 2026, disclosing under Item 2.03 the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. No specific details such as amounts, terms, parties involved, or connection to any merger/acquisition are provided in the filing summary. Sector is not specified.

13-02-2026

GEE Group Inc. filed a Form 8-K on February 13, 2026 (AccNo: 0001477932-26-000817), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This constitutes a voluntary disclosure of financial results with attached exhibits. No specific revenue, earnings, balance sheet details, period-over-period comparisons, or guidance were disclosed in the provided filing information.

13-02-2026

SpyGlass Pharma, Inc. filed an 8-K on February 13, 2026, under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, appointment or resignation status, reasons for change, or any financial metrics are provided in the available information. No positive or negative impacts, quantitative data, or further context such as board composition changes are disclosed.

13-02-2026

Cambridge Acquisition Corp. filed an 8-K on 2026-02-13 under Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits), related to a merger/acquisition event. No deal structure, valuation, parties, strategic rationale, financial metrics, or other quantitative details are disclosed in the provided filing information. No positive or negative metrics reported.

13-02-2026

Live Oak Bancshares, Inc. filed an 8-K on February 13, 2026, under Item 5.02 disclosing a change involving departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 indicates financial statements and exhibits are included. No specific details such as officer names, positions affected, appointment or resignation status, reasons, or quantitative data are disclosed.

13-02-2026

Centessa Pharmaceuticals plc filed an 8-K on 2026-02-13 (AccNo: 0001193125-26-051424, Size: 189 KB) under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on key position affected (e.g., CEO, CFO), appointment or resignation status, reasons, timing, or any financial metrics are disclosed. No positive or negative governance implications can be assessed due to lack of details.

• ·AccNo: 0001193125-26-051424
• ·Filing size: 189 KB
• ·Sector: not specified

13-02-2026

Emerson Electric Co filed an 8-K on February 13, 2026, reporting under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. Item 9.01 provides financial statements and exhibits. No specific transaction details, dollar values, strategic impacts, or financial metrics are disclosed.

13-02-2026

SAGA COMMUNICATIONS INC filed an 8-K on February 13, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 indicates Financial Statements and Exhibits were included. No specific details on the officer's name, title, reason for change, timing, or any quantitative metrics are disclosed.

13-02-2026

Martin Marietta Materials Inc filed an 8-K on February 13, 2026, disclosing under Item 1.04 mine safety matters involving reporting of shutdowns and patterns of violations. No additional quantitative details, financial impacts, or operational specifics were provided in the filing summary.

13-02-2026

NORTHROP GRUMMAN CORP /DE/ filed an 8-K on February 13, 2026 (AccNo: 0001628280-26-008140), disclosing an officer change event under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers). Item 9.01 indicates Financial Statements and Exhibits were included. No specific details on the affected officer, position, action (appointment or resignation), reason, effective date, or any quantitative data are disclosed.

• ·Event Type: Officer Change
• ·Source: us_sec
• ·Sector: not specified
• ·Filing Size: 190 KB

13-02-2026

QuidelOrtho Corp filed an 8-K on February 13, 2026 (AccNo: 0001193125-26-051461), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). No specific details on the affected officer, position, reason for change, or timing are disclosed. Sector is not specified.

• ·Filing size: 130 KB

13-02-2026

Phoenix Education Partners, Inc. filed an 8-K on February 13, 2026, reporting Item 5.07: Submission of Matters to a Vote of Security Holders. No specific details on the matters voted upon, meeting date, vote results, or any quantitative outcomes are disclosed. This is a single-item mandatory disclosure with no financial metrics or directional implications provided.

13-02-2026

Hormel Foods Corp /DE/ filed an 8-K on February 13, 2026, disclosing an officer change under Item 5.02, covering departures of directors or certain officers, elections or appointments of directors or officers, and compensatory arrangements of certain officers. Item 9.01 indicates financial statements and exhibits were included, but specific details such as names, titles, reasons for change, or timing are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or other material changes are mentioned.

13-02-2026

Idea Acquisition Corp. filed an 8-K on 2026-02-13 disclosing entry into a material definitive agreement under Item 1.01, unregistered sales of equity securities under Item 3.02, departures/elections/appointments of directors/officers and compensatory arrangements under Item 5.02, amendments to articles of incorporation or bylaws under Item 5.03, other events under Item 8.01, and financial statements/exhibits under Item 9.01. No specific details on deal structure, parties, valuation, or financial metrics are provided in the filing summary. All quantitative and qualitative transaction specifics are NOT_DISCLOSED.

13-02-2026

Red Robin Gourmet Burgers Inc filed a Form 8-K on February 13, 2026, reporting under Item 1.01 entry into a material definitive agreement and under Item 9.01 financial statements and exhibits. No specific details on the agreement's nature, parties, terms, dollar value, or financial impacts are disclosed. No quantitative metrics, period-over-period comparisons, positive or negative changes, or operational data are provided in the filing summary.

13-02-2026

Edesa Biotech, Inc. filed an 8-K on February 13, 2026 (AccNo: 0001171843-26-000810), disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet details, period-over-period comparisons, guidance, or other quantitative metrics were provided in the filing description. This appears to be a voluntary earnings-related disclosure with limited accessible details for analysis.

13-02-2026

Faraday Future Intelligent Electric Inc. filed an 8-K on February 13, 2026, under Item 5.07 disclosing submission of matters to a vote of security holders, Item 8.01 for other events, and Item 9.01 for financial statements and exhibits. No specific vote outcomes, details of other events, financial metrics, or exhibit contents are disclosed. This multi-item filing provides informational updates without quantified positive or negative impacts.

13-02-2026

Quetta Acquisition Corp filed an 8-K on February 13, 2026 (AccNo: 0001493152-26-006730, Size: 256 KB) disclosing information under Item 5.02 regarding Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. No specific names, dates, details, financial metrics, or transaction information are mentioned in the filing summary. Sector not specified, and no merger/acquisition details provided.

13-02-2026

Longeveron Inc. filed an 8-K on 2026-02-13 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 indicates Financial Statements and Exhibits were included. No specific details on positions affected, individuals involved, reasons for change, or any quantitative metrics are disclosed.

13-02-2026

Bank of America Corp /DE/ filed an 8-K on February 13, 2026, under Item 8.01 Other Events (Accession No. 0000070858-26-000088, size 352 KB). No specific core event, transaction details, financial metrics, or quantitative data are disclosed in the provided filing information. This is a single-item filing reporting other material events not covered by standard 8-K items.

13-02-2026

Phoenix Energy One, LLC filed a Form 8-K on February 13, 2026 (AccNo: 0001193125-26-051726), reporting under Item 1.01 entry into a Material Definitive Agreement. Item 9.01 includes Financial Statements and Exhibits. No specific terms, dollar values, strategic details, or financial impacts of the agreement are disclosed in the provided filing summary.

13-02-2026

NutriBand Inc. filed a Form 8-K on February 13, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific events, transactions, financial metrics, or other details are disclosed in the provided filing information.

13-02-2026

BayFirst Financial Corp. filed an 8-K on 2026-02-13 disclosing under Item 5.02 a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on the individuals involved, reasons for change, timing, or impacts are disclosed.

13-02-2026

IDEXX Laboratories Inc./DE filed an 8-K on February 13, 2026 (AccNo: 0000874716-26-000007, Size: 276 KB) under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on positions affected, individuals involved, reasons for change, timing, or quantitative impacts are disclosed. This is a routine governance disclosure with no financial metrics or performance data provided.

13-02-2026

OXBRIDGE RE HOLDINGS Ltd filed an 8-K on February 13, 2026 (AccNo: 0001493152-26-006760), reporting under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. Item 9.01 discloses financial statements and exhibits. No specific details on the agreement, transaction size, parties, financial impacts, or metrics are provided in the filing summary.

13-02-2026

Delta Air Lines, Inc. filed an 8-K on February 13, 2026 (AccNo: 0001683168-26-001033), disclosing information under Item 5.02 regarding departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals, reasons for change, or impacts were provided. Sector not specified.

13-02-2026

Actinium Pharmaceuticals, Inc. filed an 8-K on February 13, 2026, under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, names, reasons for change, or quantitative data are disclosed. Sector information is not specified.

13-02-2026

ProPhase Labs, Inc. filed a Form 8-K on February 13, 2026 (AccNo: 0001493152-26-006784), disclosing Other Events under Item 8.01 and Financial Statements and Exhibits under Item 9.01. No specific details regarding the nature of the other events, financial exhibits, transaction values, metrics, or impacts are provided in the filing summary. This is a multi-item filing with no quantitative data or period-over-period comparisons disclosed.

13-02-2026

Bark, Inc. filed an 8-K on February 13, 2026, disclosing other events under Item 8.01 and financial statements and exhibits under Item 9.01. No specific details regarding the nature of the other events, contents of the exhibits, financial metrics, or transactions are provided in the filing summary. This appears to be an informational filing with no quantified positive or negative impacts disclosed.

13-02-2026

Banzai International, Inc. filed a Form 8-K on 2026-02-13 disclosing entry into a Material Definitive Agreement under Item 1.01, accompanied by Financial Statements and Exhibits under Item 9.01. No specific details on the agreement, transaction terms, financial impacts, or quantitative metrics are provided in the filing summary. No positive or negative performance metrics, comparisons, or other data are mentioned.